Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02103855 · ClinicalTrials.gov registry record · Phase 4
Switch From Calcineurin Inhibitor to Belatacept in Pancreas Transplant Recipients
A Phase 4 study, sponsored by Indiana University.
- Completed
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT02103855 is a Phase 4 study that has completed, run by Indiana University. The registered enrollment target is 6 participants.
The verdict
NCT02103855, a Phase 4 study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
Kidney damage is a major complication of current antirejection medicines used in transplantation. An increasing number of brittle diabetics are successfully receiving a pancreas transplant. One of the challenges following pancreas transplant is that a patient can develop kidney damage from one of their antirejection medicines, tacrolimus. The objective of this study is to substitute a new antirejection medicine which does not cause kidney damage, belatacept for tacrolimus in patients that have developed signs of tacrolimus related kidney damage to slow the progression of kidney disease.
Interventions
- DRUG Belatacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2014-06 |
| Est. Completion | 2016-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02103855
The ClinicalTrials.gov registry entry for NCT02103855 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Belatacept is the first listed.
NCT02103855 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02103855 about?
NCT02103855 is a clinical study titled "Switch From Calcineurin Inhibitor to Belatacept in Pancreas Transplant Recipients". Kidney damage is a major complication of current antirejection medicines used in transplantation. An increasing number of brittle diabetics are successfully receiving a pancreas transplant. One of the challenges following pancreas transplant is that a patient can develop kidney damage from one of th...
What is the current status of trial NCT02103855?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2014-06. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02103855?
The interventions under investigation include: Belatacept (DRUG).
Who is sponsoring clinical trial NCT02103855?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.